257 filings
Page 7 of 13
8-K
o2qf7rfrfk4k3gqz
5 Jun 19
Submission of Matters to a Vote of Security Holders
8:41am
8-K
t0smolps 6w
7 May 19
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:40pm
8-K
fa6hlyuj48rvnngzw3
25 Mar 19
Departure of Directors or Certain Officers
4:30pm
8-K
0u9bykgqj9e4a5tiio
13 Mar 19
Other Events
5:16pm
S-8
m3eg1sf og3
6 Mar 19
Registration of securities for employees
5:06pm
8-K
jkdmwal
6 Mar 19
Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update
4:45pm
CT ORDER
9drkny2b
17 Dec 18
Confidential treatment order
2:06pm
8-K
faee9h4qu6pyy
6 Nov 18
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
4:09pm
424B5
35ukem
13 Sep 18
Prospectus supplement for primary offering
12:00am
8-K
xq2kuhxy
13 Sep 18
Termination of a Material Definitive Agreement
12:00am
424B5
r9m28vpapljmhb3mbo
12 Sep 18
Prospectus supplement for primary offering
12:00am
8-K
qre3o2c4
12 Sep 18
Other Events
12:00am
8-K
1zcon7wyph8g
11 Sep 18
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program
12:00am
CT ORDER
v0ztq
11 Sep 18
Confidential treatment order
12:00am
8-K
5b27jf
6 Sep 18
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
12:00am
8-K
t0a6o0elde6
29 Aug 18
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study
12:00am